New cocktail of five drugs targets Hard-to-Treat bowel cancer

NCT ID NCT04689347

Recruiting now Disease control Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a combination of five chemotherapy drugs (FLIRT plus bevacizumab) as a first treatment for people with a specific type of metastatic colorectal cancer that has spread. The cancer must have a silenced MGMT gene and be microsatellite stable. The study first finds the safest dose, then checks if it helps control the cancer for at least 9 months. Only 27 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of five drugs: bevacizumab, irinotecan, leucovorin, 5-fluorouracil, and temozolomide
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with a specific genetic subtype of metastatic colorectal cancer that currently has limited targeted therapies.
What could go wrong: This is a very early, small study (27 people) testing safety and dosing. The drug combo is intense and may cause severe side effects. It's not yet known if it will improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITING

Milan, Milan, 20133, Italy
Istituto Oncologico Veneto IRCCS
RECRUITING

Padova, PD, 35128, Italy
Ospedale Santa Chiara
RECRUITING

Pisa, PI, 56126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.